Literature DB >> 18817808

Effects of the nicotinic receptor partial agonists varenicline and cytisine on the discriminative stimulus effects of nicotine in rats.

Mark G LeSage1, David Shelley, Jason T Ross, F Ivy Carroll, William A Corrigall.   

Abstract

The nicotinic partial agonist varenicline (VCL) is a recently approved medication for the treatment of tobacco dependence, yet very little preclinical research on this drug has been published. The present experiment examined the nicotinic partial agonist properties of VCL and its parent compound, cytisine (CYT), in a nicotine discrimination assay. Rats were trained to discriminate nicotine (0.4 mg/kg, s.c.) from saline using a two-lever discrimination procedure, followed by generalization and antagonism tests with VCL and CYT. Antagonism was examined across a range of nicotine doses. In generalization tests, VCL produced a maximum of 63% responding on the nicotine-appropriate lever, indicating partial generalization. In antagonism tests, VCL decreased the % responding on the nicotine-appropriate lever at 0.2 and 0.4 mg/kg nicotine, indicating antagonism of nicotine's discriminative stimulus effects. No dose of VCL produced significant effects on response rate. The two highest doses of CYT weakly substituted for nicotine, producing a maximum of 23% nicotine-appropriate responding. CYT produced a weak antagonism of the discrimination of moderate nicotine doses, but not of the training dose. These results demonstrate that VCL and CYT partially generalize to and partially antagonize nicotine's discriminative stimulus effects, consistent with a partial agonist mechanism of action.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18817808      PMCID: PMC2652851          DOI: 10.1016/j.pbb.2008.08.024

Source DB:  PubMed          Journal:  Pharmacol Biochem Behav        ISSN: 0091-3057            Impact factor:   3.533


  46 in total

Review 1.  The neurobiology of nicotine addiction: bridging the gap from molecules to behaviour.

Authors:  Steven R Laviolette; Derek van der Kooy
Journal:  Nat Rev Neurosci       Date:  2004-01       Impact factor: 34.870

2.  Effects of continuous nicotine infusion on nicotine self-administration in rats: relationship between continuously infused and self-administered nicotine doses and serum concentrations.

Authors:  Mark G LeSage; Daniel E Keyler; Greg Collins; Paul R Pentel
Journal:  Psychopharmacology (Berl)       Date:  2003-07-25       Impact factor: 4.530

3.  The role of nicotinic receptor alpha 7 subunits in nicotine discrimination.

Authors:  I P Stolerman; S Chamberlain; L Bizarro; C Fernandes; L Schalkwyk
Journal:  Neuropharmacology       Date:  2004-03       Impact factor: 5.250

4.  Continuous nicotine infusion reduces nicotine self-administration in rats with 23-h/day access to nicotine.

Authors:  Mark G LeSage; Dan E Keyler; Don Shoeman; Donna Raphael; Gregory Collins; Paul R Pentel
Journal:  Pharmacol Biochem Behav       Date:  2002-05       Impact factor: 3.533

5.  Expression and functional characterisation of a human chimeric nicotinic receptor with alpha6beta4 properties.

Authors:  Non M Evans; Suchira Bose; Giovanni Benedetti; Ruud Zwart; Kathy H Pearson; Gordon I McPhie; Peter J Craig; Jason P Benton; Stephen G Volsen; Emanuele Sher; Lisa M Broad
Journal:  Eur J Pharmacol       Date:  2003-04-11       Impact factor: 4.432

6.  Nornicotine pretreatment decreases intravenous nicotine self-administration in rats.

Authors:  T A Green; S B Phillips; P A Crooks; L P Dwoskin; M T Bardo
Journal:  Psychopharmacology (Berl)       Date:  2000-10       Impact factor: 4.530

7.  Varenicline is a partial agonist at alpha4beta2 and a full agonist at alpha7 neuronal nicotinic receptors.

Authors:  Karla B Mihalak; F Ivy Carroll; Charles W Luetje
Journal:  Mol Pharmacol       Date:  2006-06-09       Impact factor: 4.436

8.  Halogenated cytisine derivatives as agonists at human neuronal nicotinic acetylcholine receptor subtypes.

Authors:  Y E Slater; L M Houlihan; P D Maskell; R Exley; I Bermúdez; R J Lukas; A C Valdivia; B K Cassels
Journal:  Neuropharmacology       Date:  2003-03       Impact factor: 5.250

9.  Discriminative stimulus properties of nicotine: further evidence for mediation at a cholinergic receptor.

Authors:  J A Pratt; I P Stolerman; H S Garcha; V Giardini; C Feyerabend
Journal:  Psychopharmacology (Berl)       Date:  1983       Impact factor: 4.530

10.  Role of training dose in discrimination of nicotine and related compounds by rats.

Authors:  I P Stolerman; H S Garcha; J A Pratt; R Kumar
Journal:  Psychopharmacology (Berl)       Date:  1984       Impact factor: 4.530

View more
  43 in total

1.  Varenicline decreases nicotine self-administration and cue-induced reinstatement of nicotine-seeking behaviour in rats when a long pretreatment time is used.

Authors:  Bernard Le Foll; Munmun Chakraborty-Chatterjee; Shaul Lev-Ran; Chanel Barnes; Abhiram Pushparaj; Islam Gamaleddin; Yijin Yan; Maram Khaled; Steven R Goldberg
Journal:  Int J Neuropsychopharmacol       Date:  2011-09-23       Impact factor: 5.176

2.  Enhanced attenuation of nicotine discrimination in rats by combining nicotine-specific antibodies with a nicotinic receptor antagonist.

Authors:  Mark G LeSage; David Shelley; Marco Pravetoni; Paul R Pentel
Journal:  Pharmacol Biochem Behav       Date:  2012-04-04       Impact factor: 3.533

3.  Delivery of nicotine in an extract of a smokeless tobacco product reduces its reinforcement-attenuating and discriminative stimulus effects in rats.

Authors:  Andrew C Harris; Irina Stepanov; Paul R Pentel; Mark G Lesage
Journal:  Psychopharmacology (Berl)       Date:  2011-09-30       Impact factor: 4.530

Review 4.  Neuropharmacology of the interoceptive stimulus properties of nicotine.

Authors:  Thomas E Wooters; Rick A Bevins; Michael T Bardo
Journal:  Curr Drug Abuse Rev       Date:  2009-09

5.  The effects of nicotine, varenicline, and cytisine on schedule-controlled responding in mice: differences in α4β2 nicotinic receptor activation.

Authors:  Colin S Cunningham; Lance R McMahon
Journal:  Eur J Pharmacol       Date:  2010-12-21       Impact factor: 4.432

6.  Differential antagonism and tolerance/cross-tolerance among nicotinic acetylcholine receptor agonists: scheduled-controlled responding and hypothermia in C57BL/6J mice.

Authors:  Fernando B de Moura; Lance R McMahon
Journal:  Behav Pharmacol       Date:  2016-04       Impact factor: 2.293

7.  Attenuated nicotine-like effects of varenicline but not other nicotinic ACh receptor agonists in monkeys receiving nicotine daily.

Authors:  Colin S Cunningham; Megan J Moerke; Martin A Javors; F Ivy Carroll; Lance R McMahon
Journal:  Br J Pharmacol       Date:  2016-11-06       Impact factor: 8.739

8.  Multiple nicotine training doses in mice as a basis for differentiating the effects of smoking cessation aids.

Authors:  Colin S Cunningham; Lance R McMahon
Journal:  Psychopharmacology (Berl)       Date:  2013-03-14       Impact factor: 4.530

9.  Discriminative stimulus and hypothermic effects of some derivatives of the nAChR agonist epibatidine in mice.

Authors:  Jesse S Rodriguez; Colin S Cunningham; Fernando B Moura; Pauline Ondachi; F Ivy Carroll; Lance R McMahon
Journal:  Psychopharmacology (Berl)       Date:  2014-05-07       Impact factor: 4.530

10.  The discriminative stimulus effects of i.v. nicotine in rhesus monkeys: Pharmacokinetics and apparent pA2 analysis with dihydro-β-erythroidine.

Authors:  Megan J Moerke; Andy Z X Zhu; Rachel F Tyndale; Martin A Javors; Lance R McMahon
Journal:  Neuropharmacology       Date:  2016-12-08       Impact factor: 5.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.